QUINIDINE GLUCONATE by Eli Lilly and Company is mechanisms of action in patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, with little effect upon sporozites or upon pre-erythrocytic parasites. First approved in 1950.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
Quinidine gluconate is a Class Ia antiarrhythmic small molecule administered by injection for the treatment of cardiac arrhythmias including atrial flutter, atrial fibrillation, and paroxysmal supraventricular tachycardia. It works by depressing sodium current in cardiac tissue, slowing conduction and prolonging the effective refractory period to interrupt reentrant arrhythmias. Historically also used as an antimalarial agent against Plasmodium species.
Product approaching loss of exclusivity with minimal current linked job openings; career opportunities increasingly limited to niche cardiac and legacy portfolio roles.
Mechanisms of action In patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, with little effect upon sporozites or upon pre-erythrocytic parasites. Quinidine is gametocidal to Plasmodium vivax and P. malariae , but not to P. falciparum. In cardiac muscle and in…
Worked on QUINIDINE GLUCONATE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on quinidine gluconate offers minimal career growth; this is a legacy small-molecule injectable approaching or at LOE with zero linked job openings. Career value lies in operational expertise (manufacturing, compliance, supply) rather than commercial or innovation impact.